Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relinqing Granule Combined with Ciprofloxacin for Chronic Prostatitis
ChiCTR2000035212Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
- Start
- Aug 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ciprofloxacin and Relinqing granules in chronic prostatitis (CP), sponsored by Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoints: Concentration of ciprofloxacin and Relinqing markers in blood and prostatic fluid and NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom Index) score. Started Aug 2020; status: recruiting.
02
Drugs
ciprofloxacinRelinqing granules
03
Conditions
chronic prostatitis (CP)
Beyond the preview
Go deeper on ChiCTR2000035212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035212.